razoxane has been researched along with Breast Neoplasms in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (12.73) | 18.7374 |
| 1990's | 27 (49.09) | 18.2507 |
| 2000's | 16 (29.09) | 29.6817 |
| 2010's | 5 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradbury, J; Gale, J; Muthuramalingam, S | 1 |
| Hao, XM; Li, WJ; Wang, P; Zhang, J; Zhang, S; Zhang, XB | 1 |
| Brower, V | 1 |
| Bosso, G; Ceste, M; de Conciliis, E; Ferrero, G; Ferro, S; Giaretto, L; Lanfranco, C; Manfredi, R; Miglietta, L; Milanese, S; Parello, G; Simoni, C; Testore, F | 1 |
| Cunningham, D; Hawkes, EA; Okines, AF; Plummer, C | 1 |
| Albini, A; Anzà, C; Baravelli, M; Bucci, EO; Cammarota, R; Cesana, E; Donatelli, F; Noonan, DM | 1 |
| Budman, DR; Calabro, A | 1 |
| Gisterek, I; Mazur, G; Wróbel, T; Włodarska, I; Zymliński, R; Łacko, A | 1 |
| Jensen, JN; Langer, SW; Lock-Andersen, J; Mejer, J | 1 |
| Baioni, M; Ballardini, M; De Giorgi, U; Ferrari, E; Marangolo, M; Minzi, MR; Rosti, G; Zaniboni, A; Zornetta, L | 1 |
| Grilli, C; Leoni, V; Onori, N; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Abbas, J; Abou-Mourad, Y; El-Saghir, N; Mufarrij, A; Otrock, Z; Salem, Z; Shamseddine, A | 1 |
| Espié, M; Llombart, A; Marty, M; Monnier, A; Rapoport, BL; Stahalova, V | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Brouwer, RE; Uges, JW; Vollaard, AM; Wilms, EB | 1 |
| Green, MD; Ng, R | 1 |
| Steinherz, L | 1 |
| Cummings, FJ; DeWys, W; Gelman, R; Glick, J; Tormey, DC | 1 |
| Bosnjak, S; Jelić, S; Kreacić, M; Milanović, N; Nesković-Konstantinović, Z; Radulović, S; Ristović, Z; Vuletić, L | 1 |
| Bagdasarov, IuB; Min'kov, ED; Niu-Tian-de, GB; Odzharova, AA; Shkhvatsabaia, LV; Zaĭtseva, TI | 1 |
| Garin, AM; Lichinitser, MR; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B | 2 |
| Gershanovich, ML; Moiceenko, VM; Orlova, RV | 1 |
| Jurga, L; Misurová, E; Vancík, J | 1 |
| Sledge, GW | 1 |
| Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J | 1 |
| Garin, AM; Lichinitser, MP; Min'kov, ED; Nakhalova, TA; Odzharova, AA; Vyshinskaia, GV | 1 |
| Bergh, J; Davies, SL; Harris, AL; Hickson, ID | 1 |
| Bianchine, JR; Desai, A; Ewer, MS; Gams, RA; Gerber, MC; Jones, SE; Mittelman, A; Pendergrass, K; Reddy, S; Speyer, J; Spicer, D; Swain, SM; Velez-Garcia, E; Vogel, C; Wadler, S; Weisberg, S; Whaley, FS; York, M | 1 |
| Bianchine, JR; Ewer, MS; Gams, RA; Gerber, MC; Swain, SM; Whaley, FS | 1 |
| Lemez, P | 1 |
| Blum, RH | 1 |
| Conti, F; Di Lauro, K; Ferraironi, A; Giannarelli, D; Lopez, M; Maini, CL; Paoletti, G; Sciuto, R; Vici, P | 1 |
| Hellmann, K | 1 |
| Swain, SM | 2 |
| Bast, A; Boven, E; Grimbergen, JA; Kramer, K; Kuiper, K; van Acker, SA; van den Berg, DJ; van der Vijgh, WJ | 1 |
| Egorin, MJ; Fry, D; Gradishar, WJ; Liebes, L; Mendoza, S; Sparano, JA; Speyer, J; Sridhara, R | 1 |
| Bramwell, V; Moran, LA; Seymour, L | 1 |
| Bengala, C; Carnino, F; Conte, P; Del Mastro, L; Gallo, L; Lionetto, R; Michelotti, A; Montanaro, E; Rosso, R; Tibaldi, C; Venturini, M | 1 |
| Chow, W; Doroshow, JH; Gandara, D; Groshen, S; Johnson, K; Lenz, HJ; Leong, L; Margolin, K; Morgan, R; Raschko, J; Shibata, S; Somlo, G; Synold, TW; Tetef, ML; Yen, Y | 1 |
| Cortazar, P; Pazdur, R; Williams, G | 1 |
| Bos, AM; van der Graaf, WT; Willemse, PH | 1 |
| Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M | 1 |
| Marchant, J | 2 |
| Bellet, RE; Catalano, RB; Creech, RH; Engstrom, PF; Harris, DT | 1 |
| Forbes, JF | 1 |
| Ferrans, V; Green, MD; Hochster, H; Kramer, E; Meyers, M; Rey, M; Sanger, J; Speyer, JL; Wernz, JC; Zeleniuch-Jacquotte, A | 1 |
| Blum, RH; Green, MD; Hochester, H; Kramer, E; Meyers, M; Rey, M; Sanger, J; Speyer, JL; Wernz, JC; Zeleniuch-Jacquotte, A | 1 |
| Dubin, N; Ferrans, V; Green, MD; Kramer, E; Rey, M; Sanger, J; Speyer, JL; Stecy, P; Ward, C; Zeleniuch-Jacquotte, A | 1 |
| Green, MD | 1 |
7 review(s) available for razoxane and Breast Neoplasms
| Article | Year |
|---|---|
Dexrazoxane efficacy for anthracycline extravasation: use in UK clinical practice.
Topics: Adult; Aged; Anthracyclines; Antidotes; Antineoplastic Agents; Breast Neoplasms; Chelating Agents; Esophageal Neoplasms; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Middle Aged; Razoxane | 2013 |
[Cardiac toxicity in cancer therapy].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiomyopathy, Dilated; Cardiovascular Agents; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Radiotherapy, Adjuvant; Razoxane; Risk Factors; Sarcoma | 2002 |
Managing cardiotoxicity in anthracycline-treated breast cancers.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Clinical Trials, Phase III as Topic; Doxorubicin; Female; Heart; Humans; Liposomes; Neoplasm Metastasis; Paclitaxel; Razoxane; Trastuzumab | 2007 |
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Heart Diseases; Humans; Iron; Myocardium; Razoxane; Safety; Treatment Outcome | 1997 |
Overview and historical development of dexrazoxane.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane | 1998 |
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Razoxane | 1998 |
Long-term effects of adjuvant chemotherapy in breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Heart; Heart Diseases; Hodgkin Disease; Humans; Leukemia; Lymphatic Metastasis; Menopause; Menstruation; Monitoring, Physiologic; Neoplasms, Second Primary; Ovary; Razoxane | 1992 |
22 trial(s) available for razoxane and Breast Neoplasms
| Article | Year |
|---|---|
[Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Bone Marrow; Breast Neoplasms; Cardiovascular Agents; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Heart Rate; Humans; Leukocyte Count; Middle Aged; Natriuretic Peptide, Brain; Neutrophils; Razoxane; Stroke Volume; Young Adult | 2013 |
High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Count; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Leukapheresis; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Recombinant Proteins | 2003 |
Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cardiotonic Agents; Female; Humans; Middle Aged; Neoplasm Metastasis; Razoxane | 2006 |
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Female; Humans; Menopause; Middle Aged; Mitolactol; Neoplasm Metastasis; Piperazines; Razoxane; Time Factors; Vincristine | 1981 |
[An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Middle Aged; Myocardial Contraction; Razoxane; Time Factors | 1994 |
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen | 1994 |
[Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Razoxane; Treatment Outcome; Ventricular Function, Left | 1993 |
Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Infusions, Intravenous; Middle Aged; Razoxane | 1993 |
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane | 1996 |
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Fluorouracil; Heart Failure; Humans; Prospective Studies; Razoxane; Risk Factors; Survival Analysis; Treatment Outcome | 1997 |
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Disease-Free Survival; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Heart Failure; Humans; Middle Aged; Prospective Studies; Razoxane; Treatment Outcome | 1997 |
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Drug Monitoring; Epirubicin; Female; Heart; Heart Rate; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radionuclide Imaging; Razoxane; Sarcoma; Ventricular Function, Left | 1998 |
Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Half-Life; Humans; Middle Aged; Neutropenia; Paclitaxel; Razoxane; Remission Induction; Ventricular Function, Left | 1999 |
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Failure; Humans; Injections, Intravenous; Middle Aged; Razoxane; Treatment Outcome; Ventricular Dysfunction, Left | 2000 |
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cations; Chromatography, High Pressure Liquid; Cohort Studies; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Razoxane; Time Factors | 2001 |
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Economics, Pharmaceutical; Female; Fluorouracil; Health Care Costs; Heart; Heart Diseases; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Razoxane; Sensitivity and Specificity | 1996 |
Phase II study of ICRF-159 in refractory metastatic breast cancer.
Topics: Blood Cell Count; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Neoplasm Metastasis; Piperazines; Razoxane; Time Factors | 1979 |
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Heart Failure; Humans; Life Tables; Middle Aged; Razoxane; Regression Analysis; Survival Analysis; Ventricular Function, Left | 1992 |
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Prospective Studies; Razoxane | 1990 |
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Tolerance; Female; Fluorouracil; Heart; Heart Failure; Humans; Middle Aged; Myocardium; Piperazines; Radionuclide Imaging; Random Allocation; Razoxane; Stroke Volume | 1988 |
26 other study(ies) available for razoxane and Breast Neoplasms
| Article | Year |
|---|---|
Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cardiotonic Agents; Chelating Agents; Female; Heart; Heart Failure; Humans; Molecular Targeted Therapy; Razoxane; Receptor, ErbB-2; Stroke Volume; Trastuzumab | 2013 |
Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Electrocardiography; Epirubicin; Female; Follow-Up Studies; Heart Failure; Humans; Incidence; Life Expectancy; Middle Aged; Neoplasm Metastasis; Razoxane; Retrospective Studies | 2008 |
Cardiotoxicity in patients treated with bevacizumab is potentially reversible.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Labeling; Early Termination of Clinical Trials; Epirubicin; Female; Fluorouracil; Heart Failure; Humans; Lymphoma, Large B-Cell, Diffuse; Meta-Analysis as Topic; Paclitaxel; Prednisone; Razoxane; Remission, Spontaneous; Rituximab; Trastuzumab; Vincristine | 2011 |
Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Heart; Humans; Lapatinib; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Razoxane; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2011 |
In vitro search for synergy and antagonism: evaluation of docetaxel combinations in breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disulfiram; Docetaxel; Drug Interactions; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epirubicin; Female; Humans; Paclitaxel; Razoxane; Taxoids; Tretinoin; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Dexrazoxane-a promising antidote in the treatment of accidental extravasation of anthracyclines.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Razoxane | 2003 |
Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions.
Topics: Adult; Anaphylaxis; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Razoxane | 2004 |
Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chelating Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Doxorubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Intralesional; Randomized Controlled Trials as Topic; Razoxane; Skin Ulcer; Thorax; Wound Healing | 2004 |
Intrapleural extravasation of epirubicin, 5-fluouracil, and cyclophosphamide, treated with dexrazoxane.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Humans; Mastectomy, Segmental; Middle Aged; Pleural Cavity; Pleural Effusion; Razoxane; Treatment Outcome | 2006 |
Early breast cancer therapy and cardiovascular injury.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiotonic Agents; Cardiovascular Diseases; Female; Humans; Razoxane; Treatment Outcome | 2008 |
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Doxorubicin; Echocardiography; Electrocardiography; Female; Fluorouracil; Heart; Heart Failure; Humans; Infusions, Intravenous; Lymphatic Metastasis; Middle Aged; Razoxane; Remission Induction; Risk Factors; Stroke Volume; Ventricular Function, Left | 1995 |
[The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Interactions; Female; Fluorouracil; Heart; Humans; Middle Aged; Razoxane; Remission Induction | 1994 |
New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Razoxane | 1995 |
Paclitaxel doublets in metastatic breast cancer: Eastern Cooperative Oncology Group and Hoosier Oncology Group Studies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Female; Heart; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Prospective Studies; Randomized Controlled Trials as Topic; Razoxane | 1996 |
[Cardioxan as a cardioprotector in antineoplastic chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Heart Failure; Humans; Radionuclide Ventriculography; Razoxane; Treatment Outcome | 1996 |
Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Breast Neoplasms; DNA Topoisomerases, Type II; Down-Regulation; Drug Resistance, Neoplasm; Humans; Male; Razoxane; RNA, Messenger; Testicular Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
Topics: Acute Disease; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Heart; Humans; Leukemia, Myeloid; Middle Aged; Razoxane | 1997 |
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Antioxidants; Breast Neoplasms; Cardiomyopathies; Catechin; Chelation Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Electrocardiography; Female; Flavonoids; Flavonols; Free Radical Scavengers; Free Radicals; Humans; Hydroxyethylrutoside; Iron; Iron Chelating Agents; Kaempferols; Mice; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Ovarian Neoplasms; Quercetin; Razoxane; Rutin; Telemetry; Tumor Cells, Cultured; Weight Loss | 1997 |
Doxorubicin-induced cardiomyopathy.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Doxorubicin; Heart Failure; Humans; Razoxane | 1999 |
Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Drug Administration Schedule; Epirubicin; Evidence-Based Medicine; Female; Heart; Heart Failure; Humans; Neoplasms; Odds Ratio; Randomized Controlled Trials as Topic; Razoxane; Time Factors; Treatment Outcome | 1999 |
Developing drugs to decrease the toxicity of chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drugs, Investigational; Heart; Humans; Liposomes; Razoxane | 2001 |
A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cryotherapy; Cyclophosphamide; Dimethyl Sulfoxide; Edema; Enzyme Inhibitors; Epirubicin; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Free Radical Scavengers; Hand; Humans; Hydrocortisone; Infusions, Intravenous; Iron Chelating Agents; Pain; Pain Management; Razoxane; Ulcer | 2001 |
Prophylactic chemotherapy following breast cancer: a personal experience.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Female; Humans; Levodopa; Neoplasm Metastasis; Razoxane; Tamoxifen | 1977 |
Letter: Curability of breast cancer.
Topics: Breast Neoplasms; Female; Humans; Piperazines; Razoxane | 1976 |
ICRF-187 and doxorubicin-induced cardiac toxicity.
Topics: Breast Neoplasms; Chelating Agents; Doxorubicin; Female; Heart; Humans; Piperazines; Razoxane | 1989 |
Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Interactions; Female; Fluorouracil; Heart; Humans; Piperazines; Razoxane | 1987 |